HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lubiprostone.

Abstract
Sucampo Pharmaceuticals Inc and Takeda Pharmaceutical Co Ltd are developing, a ClC-2 chloride channel activator and a bicyclic member of a series of fatty acid compounds, for the potential treatment of a number of gastrointestinal conditions, including constipation, irritable bowel syndrome, postoperative bowel dysfunction and opioid bowel dysfunction.
AuthorsJohn P Winpenny
JournalIDrugs : the investigational drugs journal (IDrugs) Vol. 8 Issue 5 Pg. 416-22 (May 2005) ISSN: 1369-7056 [Print] England
PMID15883925 (Publication Type: Journal Article, Review)
Chemical References
  • Fatty Acids
  • Lubiprostone
  • Alprostadil
Topics
  • Alprostadil (adverse effects, analogs & derivatives, therapeutic use)
  • Constipation (drug therapy)
  • Diarrhea (chemically induced)
  • Fatty Acids (therapeutic use)
  • Headache (chemically induced)
  • Humans
  • Lubiprostone
  • Nausea (chemically induced)
  • Randomized Controlled Trials as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: